摘要
目的:系统评价芪参益气滴丸的有效性和安全性,为临床应用和研究提供依据。方法:检索芪参益气滴丸治疗冠心病的随机对照试验(randomized controlled trials,RCTs),无盲法和语言限制;筛选符合纳入标准的RCTs,依据Jadad评分法进行文献的质量评价,并采用RevMan5.2软件进行Meta分析。结果:共纳入25篇文献,有5篇为高质量文献,占所有纳入研究的20%。按亚组分型和疗效评价分组进行Meta分析。结果:在改善心绞痛症状方面,以芪参益气滴丸作为干预药物,与对照组别比较,芪参益气滴丸的疗效均优于对照药物([RR=1.18,95%CI(1.10,1.26)],[RR=1.20,95%CI(1.09,1.32)])。在改善心电图方面,芪参益气滴丸与对照药物比较,芪参益气滴丸的疗效优于对照药[RR=1.31,95%CI(1.08,1.6)]。硝酸甘油停减率方面,芪参益气滴丸组优于对照组[RR=1.12,95%CI(1.02,1.23)]。改善心功能方面,芪参益气滴丸组优于对照组([MD-3.41,95%CI(-6.87,0.05)],[MD-6.59,95%CI(-10.47,-2.72)],[MD-7.04,95%CI(-9.22,-4.85)],[MD 5.58,95%CI(3.53,7.62)])。结论:在常规治疗基础上合用芪参益气滴丸较单纯常规治疗可进一步改善冠心病的临床症状、心电图疗效、硝酸甘油用量、心功能指标,安全性好。
Objective： To systematically review the efficacy and safety of Qishenyiqi drop pill for coronary heart disease（ CHD）. Meth- ods： All the randomized controlled trials（ RCTs） that used Qishenyiqi Drop Pill for the treatment of coronary heart disease were retrieved from Pubmed,Cochrane library,China Biology Medicine disc（ CBM）,CNKI,and WANFANG DATA. RevMan 5. 2 was used for analysis. Results： Twenty five RCTs including 6246 patients met the inclusion criteria. Five trials were adequate in methodological quality. Five trials were double-blinded. Compared with the contrast group,the treatment group showed significant higher total effectiveness rate（ [RR = 1. 18,95% CI（ 1. 10,1. 26） ],[RR = 1. 20,95% CI（ 1. 09,1. 32） ]） at improving angina symptoms. The treatment group showed effectiveness rate [RR = 1. 31,95% CI（ 1. 08,1. 6） ]at ameliorating the electrocardiogram effect,the control group showed no statisti- cally significant difference[RR = 1. 15,95% CI（ 0. 89,1. 5） ]. It showed significantly better result in the reduction of nitroglycerin [RR = 1. 12,95% CI（ 1. 02,1. 23） ]. In terms of the cardiac function,the treatment group was better than the control group（ P 0. 01）,（ [MD-3. 41,95% CI（-6. 87,0. 05） ],[ MD-6. 59,95% CI（-10. 47,2. 72） ],[ MD-7. 03,95% CI（-9. 22,-4. 85） ],[ MD 5. 58,95% CI（ 3. 53,7. 62） ]）. There were no serious side-effects reported in the trials. Conclusion： The present Meta-analysis suggests that on the basis of conventional western medicine,Qishenyiqi Drop Pilli is helpful to improve symptoms,alleviate the ischemia of electro- cardiogram,improve the reduction of nitroglycerin and cardiac function with reliable safety.
出处
《世界中医药》
CAS
2013年第12期1384-1388,共5页
World Chinese Medicine
基金
"重大新药创制"科技重大专项(编号:2009ZX09502-031)
国家中医药管理局中医药行业科研专项(编号:200707001
201007001)
国家自然科学基金项目(编号:81030063)
关键词
芪参益气滴丸
冠心病
系统评价
META分析
Qishenyiqi drop pill
Coronary heart disease
Systematic review
Meta-analysis
